Home » Stability at Head of FDA Good for Biotech, Says GlycoMimetics CEO
Stability at Head of FDA Good for Biotech, Says GlycoMimetics CEO
Margaret Hamburg will, presumably, remain chief of the Food and Drug Administration into a second term for President Barack Obama. And that’s good for the biotech industry, said Rachel King, CEO of Gaithersburg, Md.-based GlycoMimetics and a board member of her industry’s trade group, BIO.
Washington Business Journal
Washington Business Journal
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct